このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Unichem Laboratories マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Pabitrakumar Bhattacharyya

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	n/a
経営陣の平均在職期間	6.1yrs
取締役会の平均在任期間	1.1yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Pabitrakumar Bhattacharyya (55 yo)

less than a year

在職期間

Mr. Pabitrakumar Kalipada Bhattacharyya serves as a Managing Director and Director at Unichem Laboratories Limited since August 10, 2023. Mr. Bhattacharyya brings rich experience from organizations like Su...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Sandip Ghume	Deputy Chief Financial Officer	no data	₹10.75m	データなし
Pradeep Bhandari	Head of Legal & Company Secretary	4.9yrs	₹9.66m	データなし
Pabitrakumar Bhattacharyya	MD & Director	less than a year	データなし	データなし
Jalesh Burye	Chief Quality & Compliance Officer	no data	データなし	データなし
Prasad Joshi	Vice President of Human Resources & ER	16.1yrs	₹7.48m	データなし
Vinod Behl	Head of Projects & Investments	no data	₹2.10m	データなし
Dhananjay Sathe	Chief Scientific & Compliance Officer	no data	データなし	データなし
Ashwani Kumar	Chief Manufacturing & Compliance Officer	no data	データなし	データなし
Bhagwat Dhingra	Chief Executive of Domestic Pharma	11.9yrs	₹13.62m	データなし
Scott Delaney	President of North America & CEO of North America	6.1yrs	データなし	データなし
P. Deshpande	Vice President of Chemical of Research and Development	no data	₹593.35k	データなし
Supriya Mody	Associate Vice President of International Business	no data	₹3.82m	1.35% ₹ 507.4m

6.1yrs

平均在職期間

66yo

平均年齢

経験豊富な経営陣: 506690の経営陣は経験豊富で経験豊富です（平均在職期間は6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Pabitrakumar Bhattacharyya	MD & Director	less than a year	データなし	データなし
Prakash Mody	Chairman	50.1yrs	₹59.24m	16.21% ₹ 6.1b
Arun Todarwal	Independent Director	no data	データなし	データなし
Pranay Godha	Non-Executive Non-Independent Director	less than a year	データなし	データなし
Priti Puri	Additional Independent Non-Executive Director	1.3yrs	データなし	データなし
Anand Kusre	Independent Director	no data	データなし	データなし

1.1yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 506690の取締役会は経験豊富ではない ( 1年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Unichem Laboratories マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

Recent updates

Unichem Laboratories Limited, Annual General Meeting, Aug 08, 2024

Axsome Therapeutics, Inc. Settles Sunosi (solriamfetol) Patent Litigation with Unichem Laboratories Ltd

Unichem Laboratories Limited Announces the Resignation of Sandip Ghume as Deputy Chief Financial Officer, Effective June 30, 2024

Full year 2024 earnings released: ₹10.01 loss per share (vs ₹28.72 loss in FY 2023)

Unichem Laboratories Limited to Report Q4, 2024 Results on May 22, 2024

Third quarter 2024 earnings released: EPS: ₹11.93 (vs ₹9.08 loss in 3Q 2023)

Unichem Laboratories Limited to Report Q3, 2024 Results on Feb 05, 2024

Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg

Second quarter 2024 earnings released: ₹3.48 loss per share (vs ₹10.04 loss in 2Q 2023)

Unichem Laboratories Limited to Report Q2, 2024 Results on Nov 01, 2023

Unichem Laboratories Limited, Annual General Meeting, Sep 25, 2023

Insider recently sold ₹12m worth of stock

Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors

Insider recently sold ₹1.5m worth of stock

First quarter 2024 earnings released: ₹0.09 loss per share (vs ₹3.32 loss in 1Q 2023)

Non-Executive Independent Director recently sold ₹10m worth of stock

Full year 2023 earnings released: ₹28.72 loss per share (vs ₹4.70 profit in FY 2022)

Third quarter 2023 earnings released: ₹9.08 loss per share (vs ₹2.01 loss in 3Q 2022)

Krka Reportedly Eyes Promoter Stake in Unichem Laboratories

Insufficient new directors

Second quarter 2023 earnings released: ₹10.04 loss per share (vs ₹1.82 loss in 2Q 2022)

Unichem Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Unichem Laboratories Limited Receives ANDA Approval for Extended Phenytoin Sodium Capsules USP, 100 Mg from United States Food and Drug Administration

Unichem Laboratories Limited Receives ANDA Approval for Carbamazepine Tablets USP

Unichem Laboratories Limited Receives ANDA Approval for Its Quetiapine Extended-Release Tablets

Unichem Laboratories Limited Receives ANDA Approval for its Labetalol Hydrochloride Tablets, USP 100 Mg, 200 Mg, and 300 Mg from the United States Food and Drug Administration

Unichem Laboratories Limited to Report Q1, 2023 Results on Aug 09, 2022

Upcoming dividend of ₹4.00 per share

Full year 2022 earnings released: EPS: ₹4.70 (vs ₹4.88 in FY 2021)

Unichem Laboratories Limited, Annual General Meeting, Aug 09, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Unichem Laboratories Limited Recommends Final Dividend for the Year Ended March 31, 2022

Unichem Laboratories Limited to Report Q4, 2022 Results on May 27, 2022

Insufficient new directors

Unichem Laboratories Limited Receives ANDA Approval for Its Divalproex Sodium Extended-Release Tablet

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings released: ₹1.82 loss per share (vs ₹1.24 profit in 2Q 2021)

Upcoming dividend of ₹4.00 per share

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Receives Tentative USFDA Approval for ANDA of Aripiprazole Tablets

Full year 2021 earnings released: EPS ₹4.88 (vs ₹8.55 loss in FY 2020)

Unichem Laboratories Limited Recommends Dividend for the Year Ended March 31, 2021

Unichem Laboratories Limited Announces That It Has Received ANDA Approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg

Insider recently bought ₹2.3m worth of stock

Unichem Laboratories Limited Receives ANDA Approval for Its Guanfacine Tablets, USP 1 Mg and 2 Mg from the United States Food and Drug Administration

New 90-day high: ₹332

Unichem Laboratories Limited Receives Anda Approval for Its Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg from the United States Food and Drug Administration

New 90-day high: ₹294

Third quarter 2021 earnings released: EPS ₹3.35 (vs ₹2.07 loss in 3Q 2020)

Unichem Laboratories Limited Receives ANDA Approval for its Zonisamide Capsules, USP 25 mg, 50 mg and 100 mg from USFDA

Unichem Laboratories Limited to Report Q3, 2021 Results on Jan 30, 2021

New 90-day high: ₹286

Unichem Laboratories Limited Receives ANDA Approval from USFDA for Unichem's Celecoxib Capsules, 50 Mg, 100 Mg, 200 Mg, and 400 Mg

New 90-day high: ₹285

Unichem Laboratories Limited Receives ANDA Approval for Atenolol and Chlorthalidone Tablet

New 90-day low: ₹237

Second quarter 2021 earnings released: EPS ₹1.24

First half earnings released

Upcoming Dividend of ₹4.00 Per Share

First quarter earnings released

New 90-day high - ₹214

CEO（最高経営責任者

在職期間

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /14